Pre-made Anifrolumab benchmark antibody ( Whole mAb, anti-IFNAR1 therapeutic antibody, Anti-AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-026
Pre-Made Anifrolumab biosimilar, Whole mAb, Anti-IFNAR1 Antibody: Anti-AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Anifrolumab is a monoclonal antibody designed for the treatment of systemic lupus erythematosus (SLE). It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Anifrolumab biosimilar, Whole mAb, Anti-IFNAR1 Antibody: Anti-AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||4qxg:HL|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Medarex;Medical University of Vienna;MedImmune|
|Conditions Approved||Systemic lupus erythematosus|
|Conditions Active||Lupus nephritis|
|Development Tech||Medarex UltiMAb Mouse|